US WorldMeds, LLC Acquires Solstice Neurosciences, Inc. For $35.7 Million
8/13/2010 8:44:17 AM
More...
|
Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
2/11/2008 9:10:14 AM
More...
|
Solstice Neurosciences, Inc. Announces New CEO
12/21/2007 7:15:35 AM
More...
|
Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10/11/2007 9:24:25 AM
More...
|
Solstice Neurosciences, Inc. Presents Escalating Dose Study at International Congress in Istanbul, Turkey
6/15/2007 10:58:48 AM
More...
|
Solstice Neurosciences, Inc. Announces Commercialization Agreement
5/15/2007 10:39:41 AM
More...
|
Exclusive Licensing Agreement Reached Between Solstice Neurosciences, Inc. And DreamPharma Corporation For Cosmetic And Therapeutic Uses Of Myobloc(R)/NeuroBloc(R) In Korea
7/6/2006 12:14:26 PM
More...
|
Solstice Neurosciences, Inc. Release: MYOBLOC(R) (Botulinum Toxin Type B) Gains Expanded Access In First Coast Service Options' Florida And Connecticut Medicare Programs
6/15/2006 12:46:54 PM
More...
|
PainCare Holdings, Inc. (PRZ) Clarifies Relationship With Solstice Neurosciences, Inc.
5/11/2006 1:09:28 PM
More...
|
Solstice Neurosciences, Inc. Release: Noridian Part B Carrier Grants A Single Coverage Policy For MYOBLOC Botulinum Toxin Type B And Botulinum Toxin Type A
5/2/2006 10:55:19 AM
More...
|
|